Multicentre, prospective, randomised, open-label, blinded end point trial of the efficacy of allopurinol therapy in improving cardiovascular outcomes in patients with ischaemic heart disease: protocol of the ALL-HEART study
Introduction Ischaemic heart disease (IHD) is one of the most common causes of death in the UK and treatment of patients with IHD costs the National Health System (NHS) billions of pounds each year. Allopurinol is a xanthine oxidase inhibitor used to prevent gout that also has several positive e...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Published: |
BMJ Publishing Group
2016
|
| Online Access: | https://eprints.nottingham.ac.uk/38689/ |